A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa (ShigOraVax)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04312906|
Recruitment Status : Completed
First Posted : March 18, 2020
Last Update Posted : July 20, 2022
This study aims to address the paucity of accurate incidence data of diarrheal diseases associated with Shigella in Zambia and Burkina Faso. Given the limited feasibility of the current complex diagnostic methods used to detect Shigella in endemic and developing countries due to the costs, the none availability of reagents and a requirement of expensive and complex machinery, we suggest to use a rapide, easy-to-use, cost-effective, and robust Polymerase Chain Reaction (PCR) based rapid tool, the Loop-mediated isothermal amplification (LAMP) based diagnostic assay (ES-RLDT). This baseline study will enable us to generate an accurate estimate of Shigella incidence so as to inform future trials' designs of an oral vaccine development (ShigOraVax) in Burkina Faso and Zambia.
This project is part of the EDCTP2 programme supported by the European Union under grant agreement "No RIA2018V-2308
|Condition or disease||Intervention/treatment|
|Diarrhea Diarrhea Infectious||Other: no intervention|
This is an observational, cohort study to determine the incidence of Shigella in children under 5 years in Zambia and Burkina Faso.
We will first identify the population at risk i.e children that will form the cohort of children to be followed up in the study. In Zambia, this will be done through a household census that will be conducted to identify children under 5 years in the catchment areas served by the selected health facility. In Burkina Faso, the study will be conducted in the Ouagadougou Health and Demographic Surveillance System (OHDSS) catchment area. Children under five years old will be randomly selected from the OHDSS database. The heads of households or guardians of the randomly selected children will be approached for the informed consenting process to enrol into the cohort study.
We will then follow up these children using active and passive surveillance systems follow for the duration of the study. During passive follow-up, a surveillance system will be set up at the selected health facilities serving the catchment populations. Parents/guardians of enrolled children will be asked to take their child to designated health facilities once they develop an episode of diarrhoea. At presentation, a clinical evaluation will be performed on the child and the data recorded. A stool sample/rectal swab will then be collected. Once a stool sample is tested positive for Shigella, the participant will be actively followed up and monitored on days 3, 5, 7 and 9 to inquire about the disease outcome and to collect blood and stool samples.
Active follow-ups will include a combined home and clinic visits. The parents or guardians of participants enrolled in the study will be contacted through phone calls and/or home visits by trained study staff every month to collect information on the child health status. They will enquire on whether the child had an episode of diarrhoea and fever in the preceding four weeks, the use of healthcare services for the diarrhoea episode and any treatment received for the diarrhoea and fever. If an episode of diarrhoea is detected during any of the active visits, the parents/guardians will be encouraged to take the child to the clinic for appropriate management. The child will then go through the passive surveillance procedures.
MSD cases will be defined as a three or more loose stools or at least one bloody/mucoid stool within a 24 hour period (WHO, 2005). A diarrhoea episode will be defined as new if the diarrhea definition is met after seven days free of diarrhoea or dysentery. A Shigella case will be defined as any loose stool with LAMP confirmed Shigella.
In Ndola, the burden of shigella disease will be determined in under five children presenting with moderate to severe diarrhea and admitted to Arthur Davison children's hospital in Ndola.
|Study Type :||Observational|
|Actual Enrollment :||1334 participants|
|Official Title:||A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa|
|Actual Study Start Date :||September 14, 2020|
|Actual Primary Completion Date :||November 30, 2021|
|Actual Study Completion Date :||November 30, 2021|
- Other: no intervention
- Incidence of Shigella diarrheal disease in children under fives in Zambia and Burkina Faso [ Time Frame: 1 year ]number of children testing Shigella positive during course of study
- Attributable fraction for Shigella among all-cause MSD in children under 5 years [ Time Frame: 1 year ]the number of children presenting with MSD with confirmed Shigella
- Incidence of ETEC diarrheal disease in children under fives in Zambia and Burkina Faso [ Time Frame: 1 year ]the number of children presenting with MSD with confirmed ETEC
- Antimicrobial susceptibility/resistance of isolates to common antibiotics [ Time Frame: 1 year ]Proportion of shigella isolates resistant to common antibiotics
- Predictive accuracy of the modified diarrhoea severity scoring tool among children presenting with MSD [ Time Frame: 1 year ]Proportion of MSD cases confirmed by the modified severity score
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04312906
|Ouagadougou, Burkina Faso|
|Arthur Davidson Childrens Hospital|
|Ndola, Copperbelt, Zambia, 10101|
|Chainda South Health Facility|
|Lusaka, Zambia, 10101|
|Study Director:||Sophie Hourard||European Vaccine Initiative|